Sarepta Therapeutics (NASDAQ:SRPT) Earns Overweight Rating from Cantor Fitzgerald
Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $163.00 price objective on the biotechnology company’s stock. A number of other research analysts have also commented on the company. Scotiabank began coverage on Sarepta […]
Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a research report sent to investors on Tuesday,Benzinga reports. Cantor Fitzgerald currently has a $163.00 price objective on the biotechnology company’s stock. A number of other research analysts have also commented on the company. Scotiabank began coverage on Sarepta […]
